|
CANCERS BRONCHIQUES A PETITES CELLULES
CHIMIOTHERAPIE CONCENTREE |
|
|
Référence |
chimiothérapie (mg/m²) |
stade |
nb pts |
RO |
p |
SM |
p |
|
Pujol, 1997 |
CPA-Epir-VP16-CDDP |
ME |
NS |
S |
|||
|
1. 1800 60 330 120 +GM |
65 |
87% |
8,9m |
||||
|
2. 1200 40 225 100 |
60 |
74% |
11m |
||||
|
Ardizzoni, 2002 |
CPA-ADR-VP16 |
ML+ME |
NS |
NS |
|||
|
1. 1 45 300 |
119 |
79% |
54 s |
||||
|
2. 1,2 55 375 + G |
125 |
84% |
52 s |
Références
(1) Pujol JL, Douillard JY, Riviere A, Quoix E, Lagrange JL, Berthaud P et al. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study. J Clin Oncol 1997; 15(5):2082-2089.
(2) Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H et al. Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol 2002; 20(19):3947-3955.